Change to HY 2022 results date

Source: RNS
RNS Number : 3244Z
Haleon PLC
13 September 2022

13 September 2022


Haleon plc


Change of Haleon HY 2022 results date


We were deeply saddened by the passing of Her Majesty Queen Elizabeth II and join the people of the UK, the Commonwealth and world in mourning her passing and offer our heartfelt condolences to the Royal Family.


Respectful of the news that the State Funeral is taking place on Monday 19th September 2022 and the announcement that this will be a UK bank holiday we have decided to move our HY 2022 results release from Monday 19th September to Tuesday 20th September 2022.


The results release will be available on the investors section of the Haleon website at 7am BST (8am CET) with a recorded presentation available shortly after. An analyst and investor Q&A call will subsequently take place at 11:30am. Dial in details will be published on the website and shared in the HY release.  A replay of the Q&A call will also be available on the website shortly after the event.




About Haleon


Haleon (LSE: HLN) is a global leader in consumer health, with brands trusted by millions of consumers globally. The group employs over 22,000 people across 170 markets, who are united by Haleon's purpose - to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit 



Contact Details:










This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.